ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy

Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey

(2016) G. Kees Hovingh et al.   ATHEROSCLEROSIS

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

(2016) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2016) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet

(2016) Raul D Santos   Lancet Diabetes & Endocrinology

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

(2016) Naveed Sattar et al.   Lancet Diabetes & Endocrinology

Impact of Postdischarge Statin Withdrawal on Long-Term Outcomes in Patients With Acute Myocardial Infarction

(2015) Min Chul Kim et al.   AMERICAN JOURNAL OF CARDIOLOGY

Frequency of High-Risk Patients Not Receiving High-Potency Statin (from a Large Managed Care Database)

(2015) Fatima Rodriguez et al.   AMERICAN JOURNAL OF CARDIOLOGY

Primary Risk Prevention in the Elderly: Use Clinician-Patient Discussions, Not Automatic Statin Prescribing

(2015) Neil J. Stone et al.   AMERICAN JOURNAL OF MEDICINE

PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?

(2015) Miguel Cainzos-Achirica et al.   ANNALS OF INTERNAL MEDICINE

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline

(2015) John R. Downs et al.   ANNALS OF INTERNAL MEDICINE

IMPROVE-IT clinical implications. Should the “high-intensity cholesterol-lowering therapy” strategy replace the “high-intensity statin therapy”?

(2015) Luis Masana et al.   ATHEROSCLEROSIS

A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy

(2015) Carlos Aguiar et al.   ATHEROSCLEROSIS SUPPLEMENTS

Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology

(2015) Viveca Gyberg et al.   Cardiovascular Diabetology

Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials

(2015) Yi Ding et al.   CLINICAL NUTRITION

Pathophysiology of diabetic dyslipidaemia: where are we?

(2015) Bruno Vergès   DIABETOLOGIA

PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials

(2015) Kristopher J. Swiger et al.   DRUG SAFETY

Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution

(2015) Maarten L. Simoons et al.   EUROPEAN HEART JOURNAL

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

(2015) Michael J. Lipinski et al.   EUROPEAN HEART JOURNAL

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials

(2015) James McKenney et al.   Journal of Clinical Lipidology

Lowering LDL Cholesterol Is Good, but How and in Whom?

(2015) Neil J. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Drugs for Treating Dyslipidemia: Beyond Statins

(2015) Chang Ho Ahn et al.   Diabetes & Metabolism Journal

Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe

(2015) Julian P. Halcox et al.   PLoS One

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

(2014) Daniel Gaudet et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy

(2014) Kimberly A. Gudzune et al.   ANNALS OF INTERNAL MEDICINE

Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review

(2014) Mary A. De Vera et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Lomitapide and Mipomersen

(2014) Daniel J. Rader et al.   CIRCULATION

Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes

(2014) Morten Hansen et al.   Current Diabetes Reports

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

(2014) Barbara Sjouke et al.   EUROPEAN HEART JOURNAL

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

(2014) Frederick J. Raal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Secondary prevention after acute myocardial infarction: Drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry

(2014) Stefano Urbinati et al.   European Journal of Preventive Cardiology

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

(2014) Barbara Sjouke et al.   Lancet Diabetes & Endocrinology

The Complexity of Measuring Clinical Complexity

(2013) Barbara J. Turner et al.   ANNALS OF INTERNAL MEDICINE

Defining Patient Complexity From the Primary Care Physician's Perspective

(2013) Richard W. Grant et al.   ANNALS OF INTERNAL MEDICINE

Defining Patient Complexity

(2013) Richard W. Grant   ANNALS OF INTERNAL MEDICINE

Defining Patient Complexity

(2013) Joseph M. Cerimele   ANNALS OF INTERNAL MEDICINE

Treating Our Societal Scotoma: The Case for Investing in Geriatrics, Our Nation's Future, and Our Patients

(2013) Rosanne M. Leipzig   ANNALS OF INTERNAL MEDICINE

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

(2013) Amirhossein Sahebkar et al.   CARDIOVASCULAR DRUGS AND THERAPY

Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective

(2013) Amir Hooshang Mohammadpour et al.   CLINICAL PHARMACOKINETICS

Niacin

(2013) Henry N. Ginsberg et al.   CURRENT OPINION IN LIPIDOLOGY

2013 ESC guidelines on the management of stable coronary artery disease

(2013)   EUROPEAN HEART JOURNAL

Diagnosis and treatment of familial hypercholesterolaemia

(2013) G. Kees Hovingh et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease

(2013) Gianluigi Savarese et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study

(2013) Philippa J Talmud et al.   LANCET

Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

(2013) Ramón Estruch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toward a Modern Mediterranean Diet for the 21st Century

(2013) J. Stamler   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study

(2013) Christopher Ll Morgan et al.   BMJ Open

PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics

(2013) Rose Q. Do et al.   Current Cardiology Reports

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

(2013) Robert A Hegele et al.   Lancet Diabetes & Endocrinology

Exercise effects on lipids in persons with varying dietary patterns—does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through Defined Exercise I

(2012) Kim M. Huffman et al.   AMERICAN HEART JOURNAL

In This Issue: Assessing and Acting on Complexity

(2012) K. C. Stange   ANNALS OF FAMILY MEDICINE

Association of Patient-Centered Outcomes With Patient-Reported and ICD-9-Based Morbidity Measures

(2012) E. A. Bayliss et al.   ANNALS OF FAMILY MEDICINE

A Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology

(2012) M. Fortin et al.   ANNALS OF FAMILY MEDICINE

Measures of Multimorbidity and Morbidity Burden for Use in Primary Care and Community Settings: A Systematic Review and Guide

(2012) A. L. Huntley et al.   ANNALS OF FAMILY MEDICINE

A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2

(2012) Raul D. Santos et al.   ATHEROSCLEROSIS

Healthy Lifestyle Through Young Adulthood and the Presence of Low Cardiovascular Disease Risk Profile in Middle Age

(2012) Kiang Liu et al.   CIRCULATION

Design of Tumor Biomarker-Monitoring Trials: A Proposal by the European Group on Tumor Markers

(2012) G. Soletormos et al.   CLINICAL CHEMISTRY

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

(2012) et al.   EUROPEAN HEART JOURNAL

ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK

(2012) Kornelia Kotseva et al.   HEART

Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey

(2012) Raffaele Griffo et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study

(2012) Ola Vedin et al.   European Journal of Preventive Cardiology

Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes

(2011) Lutgarda Bozzetto et al.   ATHEROSCLEROSIS

Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era

(2011) Lawrence D. Lazar et al.   CIRCULATION

Heart Disease and Stroke Statistics—2012 Update

(2011) et al.   CIRCULATION

Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats

(2011) Vipin Dhote et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study

(2011) Alessandro Nobili et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

(2011) Anne C. Goldberg et al.   Journal of Clinical Lipidology

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence and Coexistence of Cardiovascular Comorbidities among the US Dyslipidemic Population Aged ≥ 65 Years by Lipid-Lowering Medication Use Status

(2011) Sean D. Candrilli et al.   POSTGRADUATE MEDICINE

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

(2010) Fatima Akdim et al.   AMERICAN JOURNAL OF CARDIOLOGY

Apolipoprotein A-I Mimetic Peptides

(2010) Courtney B. Sherman et al.   Cardiology in Review

Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction

(2010) Donald M. Lloyd-Jones et al.   CIRCULATION

Italian cardiovascular mortality charts of the CUORE project: are they comparable with the SCORE charts?

(2010) Chiara Donfrancesco et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation

(2010) Massimo Francesco Piepoli et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Combination Lipid Therapy in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular risk in women with diabetes

(2010) A.A. Rivellese et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Explaining the Decrease in Coronary Heart Disease Mortality in Italy Between 1980 and 2000

(2009) Luigi Palmieri et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease

(2009) Andrew Mente et al.   ARCHIVES OF INTERNAL MEDICINE

Medication Adherence

(2009) P. Michael Ho et al.   CIRCULATION

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

(2009) Kornelia Kotseva et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Complexity and health - yesterday's traditions, tomorrow's future

(2009) Joachim P. Sturmberg et al.   JOURNAL OF EVALUATION IN CLINICAL PRACTICE

Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery

(2008) Alexander Kulik et al.   CIRCULATION

General Cardiovascular Risk Profile for Use in Primary Care

(2008) Ralph B. D’Agostino et al.   CIRCULATION

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

(2008) R. Scott et al.   DIABETES CARE

Discontinuation of statin therapy following an acute myocardial infarction: a population-based study

(2008) S. S. Daskalopoulou et al.   EUROPEAN HEART JOURNAL

Statins in liver disease: A molehill, an iceberg, or neither?

(2008) Curtis K. Argo et al.   HEPATOLOGY

Statins for Secondary Prevention in Elderly Patients

(2008) Jonathan Afilalo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis

(2008)   LANCET

A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening

(2008) J M Reich   THORAX

The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment

(2007) M. Andrikoula et al.   DIABETES OBESITY & METABOLISM